Serial troponin I measurement predicted risk for patients with stable ischemic heart disease
Cardiology Today, 2013-Mar-14
SAN FRANCISCO — Monitoring levels of cardiac troponin I identified post-ACS patients at heightened risk for future death from CVD or HF, according to new data from the PROVE-IT TIMI 22 trial.
“Using a next-generation investigational assay for cardiac troponin, we found that the vast majority of patients who were stable after ACS 4 months previously had detectable levels of circulating troponin and that that level was strongly associated with subsequent cardiac events,” David A. Morrow, MD, director of the Levine Cardiac Intensive Care Unit at Brigham and Women’s Hospital, told Cardiology Today.